BioDelivery Sciences International, Inc. (NasdaqCM:BDSI) (BDSI) and Arius Pharmaceuticals, Inc. signed an agreement to acquire Worldwide Rights for BELBUCA™ from Endo International plc (NasdaqGS:ENDP) on December 7, 2016. The purchase price for the assets will be equal to the sum of the aggregate book value of the portion of the transferred product inventory forecasted to be used or sold by BDSI, the aggregate book value of work-in-progress inventory, and assumption of any assumed liabilities. Upon Closing, BDSI will accept transfer of the assets and assume and agree to discharge when due all applicable liabilities. The asset Purchase Price, will be paid to Endo in four quarterly installments on the last calendar day of each quarter in 2017. For the year ended on December 31, 2015, BELBUCA reported gross sales of $27 million. Furthermore, BDSI will not be responsible for future royalties or milestone payments to Endo, and Endo will not be obligated to any future milestone payments to the Company. The transaction price will not materially impact the BDSI's future cash flows , but the transaction is expected to add additional revenue and be accretive by improving BDSI's net income and earnings per share in 2017. Matthew P. Duffy of LifeSci Advisors, LLC and Susan Forman and Laura Radocaj of Dian Griesel Int'l. acted as public relations advisor for BioDelivery Sciences International.

BioDelivery Sciences International, Inc. (NasdaqCM:BDSI) and Arius Pharmaceuticals, Inc. completed the acquisition of Worldwide Rights for BELBUCA™ from Endo International plc (NasdaqGS:ENDP) on January 9, 2017.